121 completed, 43 recruiting, 22 terminated, 15 unknown. 92 Phase 2, 64 Phase 1, 28 Phase 3, 23 Not applicable, 5 Early Phase 1.
Follow Immunoglobulin Light-chain Amyloidosis: new trials by email Literature Review of Immunoglobulin Light-chain Amyloidosis trials Research Report on Immunoglobulin Light-chain Amyloidosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis Etentamig, Daratumumab, Cyclophosphamide - Amyloid Light Chain (AL) Amyloidosis | Phase 3 | Not yet recruiting | AbbVie | 370 | 2026-11-29 | 2026-08-28 |
| Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis GPRC5D CART - Relapsed/Refractory Multiple Myeloma (RRMM), Light-Chain Amyloidosis | Phase 1 | Not yet recruiting | Hadassah Medical Organization | 160 | 2026-11-01 | 2026-10-20 |
| Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine Imaging ¹⁸F-florbetaben - Monoclonal Gammopathy, Monoclonal Gammopathy of Undetermined Significance (MGUS) | Not applicable | Not yet recruiting | University of Zurich | 50 | 2026-10-01 | 2026-06-03 |
| A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement Anselamimab - AL Amyloidosis | Early Phase 1 | Not yet recruiting | Stanford University | 5 | 2026-09-01 | 2026-08-21 |
| SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders Non-Interventional Study - AL Amyloidosis, Multiple Myeloma | Recruiting | Mayo Clinic | 150 | 2026-08-25 | 2026-09-30 | |
| A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL Amyloidosis FKC289 infusion - Primary Light Chain (AL) Amyloidosis | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Fosun Kairos Biotechnology Co., Ltd. | 32 | 2026-08-01 | 2026-08-14 |
| Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis BCMA bispecific - Amyloid Light-chain Amyloidosis | Phase 2 | Not yet recruiting | Case Comprehensive Cancer Center | 64 | 2026-08-01 | 2026-08-05 |
| BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004) QLS4131 - AL Amyloidosis | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2026-07-20 | 2026-08-07 |
| A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis Belantamab mafodotin, Cyclophosphamide, Bortezomib - Amyloidosis | Phase 2 | Recruiting | GlaxoSmithKline | 60 | 2026-06-24 | 2026-07-17 |
| Evaluation of Skin Tests in Biotherapy Allergies Drug skin tests (investigating hypersensitivity to a biotherapy) - Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms | Not applicable | Recruiting | University Hospital, Angers | 70 | 2026-06-17 | 2026-06-18 |
| A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis Coagadex(R) - Acquired Factor X Deficiency | Phase 3 | Withdrawn | Kedrion S.p.A. | 2026-06-01 | 2026-06-29 | |
| A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). Teclistamab - Multiple Myeloma, AL Amyloidosis | Phase 2 | Recruiting | Shanghai Zhongshan Hospital | 30 | 2026-05-22 | 2026-08-03 |
| Hungarian National Systemic Amyloidosis Registry Systemic Amyloidosis, ATTR Amyloidosis | Recruiting | Semmelweis University | 300 | 2026-03-08 | 2026-07-08 | |
| Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis sonrotoclax, Daratumumab, Dexamethasone - AL Amyloidosis (AL), t(11;14) Positive | Phase 2 | Recruiting | Peking University People's Hospital | 39 | 2026-02-10 | 2026-07-28 |
| PET Imaging With [18F]Fluselenamyl in People With Cardiac Amyloidosis [18F]Fluselenamyl (FSA) - Cardiac Amyloidosis | Phase 1 | Enrolling by invitation | Washington University School of Medicine | 50 | 2026-01-14 | 2026-08-18 |
| A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis First-Line Dara-BorCyD Treatment - Light Chain (AL) Amyloidosis, MRD | Not applicable | Recruiting | Peking University First Hospital | 50 | 2025-12-15 | 2026-09-16 |
| One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS AL Amyloidosis, POEMS Syndrome | Recruiting | Fondazione IRCCS Policlinico San Matteo di Pavia | 100 | 2025-11-28 | 2026-05-06 | |
| Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment AL Amyloidosis, MGUS | Recruiting | Fondazione IRCCS Policlinico San Matteo di Pavia | 100 | 2025-11-17 | 2026-03-04 | |
| Teclistamab-Daratumumab in AL Amyloidosis Teclistamab, Daratumumab and Hyaluronidase-fihj - Amyloid Light-chain Amyloidosis | Phase 2 | Recruiting | Rajshekhar Chakraborty, MD | 25 | 2025-11-07 | 2026-07-13 |
| Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis GC012F Injection - Relapsed/Refractory AL Amyloidosis | Phase 1 | Recruiting | Gracell Biotechnologies (Shanghai) Co., Ltd. | 9 | 2025-10-29 | 2026-07-23 |
Showing 20 of 236. Sign in to see all of them.
Multiple Myeloma (101) · Neoplasms, Plasma Cell (65) · Leukemia, Lymphocytic, Chronic, B-Cell (64) · Lymphoma, Follicular (61) · Lymphoma, Large B-Cell, Diffuse (61) · Burkitt Lymphoma (60) · Lymphoma, Mantle-Cell (60) · Lymphoma, Non-Hodgkin (60) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (60) · Lymphoma, Large-Cell, Immunoblastic (59) · Hodgkin Disease (57) · Lymphoma, B-Cell, Marginal Zone (57) · Waldenstrom Macroglobulinemia (57) · Lymphoma, Large-Cell, Anaplastic (53)
Immune System Diseases (236) · Immunoproliferative Disorders (236) · Metabolic Diseases (236) · Neoplasms by Histologic Type (236) · Nutritional and Metabolic Diseases (236) · Proteostasis Deficiencies (235) · Paraproteinemias (229) · Neoplasms (226) · Lymphoproliferative Disorders (217) · Amyloidosis (186) · Neoplasms, Plasma Cell (171) · Hemic and Lymphatic Diseases (113) · Hematologic Diseases (112) · Blood Protein Disorders (108) · Cardiovascular Diseases (105)
Dexamethasone (51) · Melphalan (29) · Cyclophosphamide (26) · Bortezomib (25) · Calcium Dobesilate (18) · Filgrastim (18) · Peripheral Blood Stem Cell Transplantation (16) · daratumumab (16) · pomalidomide (11) · Lenalidomide (9) · dexamethasone acetate (8) · fludarabine phosphate (7) · Mycophenolic Acid (6) · Whole-Body Irradiation (6) · dexamethasone 21-phosphate (6)
Boston Medical Center (12) · Fondazione IRCCS Policlinico San Matteo di Pavia (12) · Mayo Clinic (8) · Memorial Sloan Kettering Cancer Center (8) · National Cancer Institute (NCI) (7) · Barbara Ann Karmanos Cancer Institute (6) · Prothena Biosciences Ltd. (6) · SWOG Cancer Research Network (6) · Alexion Pharmaceuticals, Inc. (5) · Fred Hutchinson Cancer Center (5) · GlaxoSmithKline (5) · The Cleveland Clinic (5) · European Organisation for Research and Treatment of Cancer - EORTC (4) · M.D. Anderson Cancer Center (4) · Nanjing University School of Medicine (4)
United States (150) · Italy (32) · China (29) · France (20) · Germany (20) · United Kingdom (17) · Spain (15) · Greece (12) · Israel (12) · Australia (11) · Belgium (10) · Netherlands (9) · Canada (8) · Austria (6) · Czechia (6)
Vaishali Sanchorawala, MD (10) · Morie A. Gertz, MD (4) · Jin Lu (3) · John A. Glaspy, MD, MPH (3) · Mazen A Hanna, MD (3) · Alan Solomon, MD (2) · David C. Seldin, MD, PhD (2) · David Maloney (2) · Heather Landau, MD (2) · Jian Li, MD (2) · Rajshekhar Chakraborty, MD (2) · Raymond Comenzo, MD (2) · Richard K. Burt, MD (2) · Scott Swenson, MD (2)
PMID 40226119, PMID 32499241, PMID 42212672, PMID 12000194, PMID 15156165, PMID 15308571, PMID 15365071, PMID 15459300, PMID 16710026, PMID 17397698, PMID 17855669, PMID 18698002, PMID 19170225, PMID 19841031, PMID 20085941, PMID 20522711, PMID 20724537, PMID 22259028, PMID 22331188, PMID 22480131, PMID 22504925, PMID 22517904, PMID 22733017, PMID 23144200, PMID 23358983, PMID 24004667, PMID 24386911, PMID 24474568, PMID 24668858, PMID 25027514, PMID 25580702, PMID 25974382, PMID 26117060, PMID 26175532, PMID 26176329, PMID 26700120, PMID 26700123, PMID 26858336, PMID 27020837, PMID 27381904, PMID 27460276, PMID 27872060, PMID 28103898, PMID 28130212, PMID 28279033, PMID 28522573, PMID 28550039, PMID 29298867, PMID 30205939, PMID 30333122
P30CA015083 (6), P30CA022453 (4), U10CA032102 (4), P30CA015704 (3), P30CA072720 (3), P30CA006973 (2), P30CA016086 (2), P30CA068485 (2), U01CA069912 (2), U10CA021115 (2), U10CA180888 (2), 2008 (1), 2009 (1), 2015 (1), 2025 (1)